In a xenograft mouse model representative of EGFR-mutated NSCLC, individual administration of either anti-PD-L1 or anti-CD73 antibodies fails to curtail tumor growth, in stark contrast to the isotype control. This evidence concerns the gene EGFR and neoplasm.